RxDoctor Payments Data

Anjana Samadder, MD

Gastroenterology · Columbus, OHNPI 1811053309

Payments from drug & device makers

$13,632in general payments, 2019–2025

Across 476 payments — averaging $28.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$7K
  • Redhill Biopharma Inc.$1K
  • Johnson & Johnson$977
  • AbbVie$738
  • Ironwood Pharmaceuticals, Inc$724
  • Sanofi$596
  • plus $2K from 21 others

What the payments were for

  • Consulting fees$8806%
  • Speaking & faculty fees$5,00037%
  • Food & beverage$7,63356%
  • Education$1191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,632 in reported general payments places this provider in the 75th percentile of 657 gastroenterology providers in Ohio.

See all gastroenterology providers in Ohio

Medicare billing

Part B allowed, 2024
$23,272
Medicare patients
83
Services billed
190

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide161$98,821
Dexlansoprazole DrDexlansoprazole145$25,872
TrulancePlecanatide31$21,332
Famotidine355$2,380
Omeprazole257$2,273
Sucralfate93$1,921
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl109$1,524
Dicyclomine Hcl51$1,110
Pantoprazole Sodium151$828
Lansoprazole14$550
Ondansetron OdtOndansetron87$473
Esomeprazole Magnesium16$310
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl18$237
Metoclopramide Hcl31$214

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$738$98,821161 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$6,850$21,33231 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 657 gastroenterology providers in Ohio.

Other gastroenterology in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →